Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d'Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF. Ceccherini-Silberstein F, et al. Among authors: bertoli a. J Virol. 2007 Oct;81(20):11507-19. doi: 10.1128/JVI.00303-07. Epub 2007 Aug 8. J Virol. 2007. PMID: 17686836 Free PMC article.
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. Among authors: bertoli a. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.
Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. Among authors: bertoli a. J Virol. 2006 Jul;80(14):7186-98. doi: 10.1128/JVI.02084-05. J Virol. 2006. PMID: 16809324 Free PMC article.
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Santoro MM, et al. Among authors: bertoli a. New Microbiol. 2006 Apr;29(2):89-100. New Microbiol. 2006. PMID: 16841549
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Santoro MM, et al. Among authors: bertoli a. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. doi: 10.1089/AID.2011.0142. Epub 2012 Apr 18. AIDS Res Hum Retroviruses. 2012. PMID: 22417570 Free PMC article.
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.
Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Alteri C, et al. Among authors: bertoli a. J Antimicrob Chemother. 2013 Oct;68(10):2205-9. doi: 10.1093/jac/dkt173. Epub 2013 May 17. J Antimicrob Chemother. 2013. PMID: 23687186
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.
Zaccarelli M, Santoro MM, Armenia D, Borghi V, Gennari W, Gori C, Forbici F, Bertoli A, Fabeni L, Giannetti A, Cicalini S, Bellagamba R, Andreoni M, Mastroianni CM, Mussini C, Ceccherini-Silberstein F, Perno CF, Antinori A. Zaccarelli M, et al. Among authors: bertoli a. J Clin Virol. 2016 Sep;82:94-100. doi: 10.1016/j.jcv.2016.07.007. Epub 2016 Jul 18. J Clin Virol. 2016. PMID: 27472519
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.
Alteri C, Surdo M, Di Maio VC, Di Santo F, Costa G, Parrotta L, Romeo I, Gori C, Santoro MM, Fedele V, Carta S, Continenza F, Pinnetti C, Bellagamba R, Liuzzi G, Orchi N, Latini A, Bertoli A, Girardi E, Alcaro S, Giuliani M, Petrosillo N, Andreoni M, Antinori A, Monforte AD, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V. Alteri C, et al. Among authors: bertoli a. J Glob Antimicrob Resist. 2016 Dec;7:1-7. doi: 10.1016/j.jgar.2016.06.005. Epub 2016 Jul 25. J Glob Antimicrob Resist. 2016. PMID: 27530997
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.
Armenia D, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta V, Vergori A, Mastrorosa I, Colafigli M, Lichtner M, di Biagio A, Maggiolo F, Rizzardini G, d'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; Italian INI-Surveillance Group. Armenia D, et al. Among authors: bertoli a. J Clin Virol. 2020 Sep;130:104534. doi: 10.1016/j.jcv.2020.104534. Epub 2020 Jul 11. J Clin Virol. 2020. PMID: 32769022 Free article.
362 results